OUTBACK / ANZGOG 0902 / GOG-0274
Giving extra chemotherapy after chemoradiation added side effects and no survival benefit, so timing matters: chemotherapy helps before radiation (INTERLACE), not after.
5-year OS 72% vs 71% (HR 0.91, not significant), 5-year PFS 63% vs 61% (Lancet Oncology 2023); 22% of the adjuvant arm did not receive the planned chemotherapy and grade 3-5 toxicity rose from 62% to 81%.
Setting
Locally advanced cervical cancer: chemoradiation followed by 4 cycles adjuvant carboplatin-paclitaxel vs chemoradiation alone
Phase
Phase 3
Sponsor
ANZGOG / NRG Oncology
Registry
Headline result
5-year OS 72% vs 71%; no benefit.
Reported
2021
Enrolled
919
In plain words
What these results mean for people, not percentages
Overall survival at 5 yearsprimarysurvival endpoint
- 72 vs 71 out of 100 alive at 5 years with CRT + adjuvant chemo compared with CRT alone; 1 more per 100.
- Roughly one extra person helped for every 100 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 9 percent lower chance of the event at any given time (hazard ratio 0.91, likely range 0.7 to 1.18).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Locally advanced cervical cancer: chemoradiation followed by 4 cycles adjuvant carboplatin-paclitaxel vs chemoradiation alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.